Published:
BioSpecifics Technologies Corp. to Present at Piper Jaffray 20th Annual Health Care Conference
LYNBROOK, N.Y., Nov. 20 /PRNewswire-FirstCall/ -- BioSpecifics
Technologies Corp. (OTC Bulletin Board: BSTC), a biopharmaceutical company
developing first in class collagenase-based products, today announced that
BioSpecifics' President, Thomas Wegman, will present at the upcoming Piper
Jaffray 20th Annual Health Care Conference on Tuesday, December 2, 2008, at
4:30pm ET at the New York Palace Hotel inNew York, NY.
A live webcast of the presentation can be accessed at
http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=BSTC&item_id=2021200.
About BioSpecifics Technologies Corp.
BioSpecifics Technologies Corp. is a biopharmaceutical company that has
developed and licensed injectable collagenase for three clinical indications:
Dupuytren's disease, Peyronie's disease and frozen shoulder (adhesive
capsulitis). It has a development and licensing agreement with Auxilium
Pharmaceuticals, Inc. Positive top line results from the Phase III clinical
trials with XIAFLEX(TM) for treatment of Dupuytren's disease were released in
June 2008. More information about the company may be found on its website at
www.biospecifics.com.
SOURCE BioSpecifics Technologies Corp.
Copyright © 2009, PRNewswire
Copyright © 2009, NewsBlaze,
Daily News
Tags: ,MTC,BIO,HEA,TDS,CCA,NY-BioSpecifics-Piper
_ _